




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ :</p> <p>C07D 471/14, 471/04, 487/04, 213/57, 241/12 // A61K 31/44, 31/505, 31/495, (C07D 471/14, 221:00, 221:00, 209:00) (C07D 471/14, 239:00, 221:00, 209:00) (C07D 471/14, 241:00, 221:00, 209:00) (C07D 471/04, 221:00, 209:00) (C07D 487/04, 241:00, 209:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/64422</p> <p>(43) International Publication Date: 16 December 1999 (16.12.99)</p>
<p>(21) International Application Number: PCT/US99/12990</p> <p>(22) International Filing Date: 8 June 1999 (08.06.99)</p> <p>(30) Priority Data: 60/088,808 9 June 1998 (09.06.98) US</p> <p>(71) Applicant (for all designated States except US): NEUROGEN CORPORATION [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): YOON, Taeyoung [KR/US]; 140 Mill Street #18-137, East Haven, CT 06512 (US).</p> <p>(74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: PYRIDO[2,3-B]INDOLIZINE DERIVATIVES AND AZA ANALOGUES THEREOF; CRF₁ SPECIFIC LIGANDS</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>Disclosed are compounds of formula (I), wherein Ar, R₁, R₂, R₃, W, X, Y, and Z are substituents as defined herein, which compounds are highly selective partial agonists or antagonists at human CRF₁ receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Pyrido[2,3-b]indolizine Derivatives and
Aza Analogues Thereof; CRF1 Specific Ligands**

BACKGROUND OF THE INVENTION

5 **Field of the Invention**

This invention relates to pyrido[2,3-b]indolizine derivatives and aza analogues thereof that selectively bind to corticotropin-releasing factor (CRF) receptors. It also relates to pharmaceutical compositions comprising such
10 compounds. It further relates to the use of such compounds in treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety.

Description of the Related Art


15 Posselt, K., *Arzneim.-Forsch.* **1978**, 28, 1056-65, describe the synthesis of 10-(4-methoxyphenyl)pyrido[2,3-b]indolizine. Volovenko et al., *Khim. Geterotsikl. Soedin.* **1991**, 6, 852, describe the synthesis of 2-chloro and 2-methylthio-10-tosylmethylpyrimido[4,5-b]indolizine.

SUMMARY OF THE INVENTION

This invention provides novel compounds of Formula I which interact with CRF receptors.

In one aspect, the invention provides pharmaceutical compositions comprising compounds of Formula I. In another aspect, it provides compositions useful in treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. These compositions include a compound of Formula I. Further, in a third aspect, the invention provides methods of treating such stress related disorders.

Accordingly, a broad aspect of the invention is directed to compounds of Formula I:



I

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, mono- or di(C₁-C₆) alkyl amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at least one of the

positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;

R₁ and R₂ independently represent

C₁-C₆ alkyl;

5 C₃-C₇ cycloalkyl;

C₃-C₇ cycloalkyl(C₁-C₆)alkyl;

C₁-C₆ alkoxy(C₁-C₆)alkyl; or

aryl(C₁-C₆)alkyl where aryl is phenyl, 1- or 2-naphthyl,

2-, 3-, or 4-pyridyl, 2- or 3-thienyl or 2-, 4 or 5-
10 pyrimidyl, each of which is optionally mono- or disubstituted with halogen, hydroxy, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, or (C₁-C₆ alkylene)-A-R₄, wherein A is O, S, NH, or N(C₁-C₆ alkyl) and R₄ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl; or

15 R₁ and R₂ taken together represent -(CH₂)_n-A-(CH₂)_m- wherein n is 2, 3 or 4, A is methylene, oxygen, sulfur, or NR₅, wherein R₅ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl, and m is 0, 1, or 2;

R₃ is C₁-C₆ alkyl, or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S,
20 NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl; and

W, X, Y, and Z are independently N or C-R₇, wherein R₇ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

These compounds are highly selective partial agonists or antagonists at CRF receptors and are useful in the diagnosis and treatment of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression and
5 anxiety.


Another aspect of the invention is directed to intermediates useful in the preparation of the compounds of Formula I.

In a further aspect, the invention provides methods for
10 making the compounds of Formula I and the intermediates for preparing such compounds.

DETAILED DESCRIPTION OF THE INVENTION

Preferred compounds of Formula I are those where Ar is phenyl substituted in the 2, 4, and 6 positions, preferably with methyl, ethyl or propyl; naphthyl substituted in the 2 and 5 6 positions, preferably with methyl, ethyl or propyl; or 3-pyridyl substituted in the 2, 4, and 6 positions, preferably with methyl, ethyl or propyl; 5-pyrimidiyl substituted in the 2, 4, and 6 positions, preferably with methyl, ethyl, or propyl. Particularly, preferred components of Formula I 10 include those where the Ar group is substituted in the 2 and 6 or the 2, 4, and 6 positions with methyl.

Preferred compounds of the invention have Formula II:



II

wherein Ar, R₁, R₂, and R₃ are as defined above for Formula I;

and


X, Y, and Z are independently N or C-R₇, wherein R₇ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

Preferred compounds of Formula II are those where X and Z are both CH and Y is CH or nitrogen. More preferred compounds

of Formula II are those where R_3 is C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl(C_1 - C_3)alkyl. Other more preferred compounds of Formula II are those where R_1 and R_2 independently represent C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl(C_1 - C_6)alkyl, $-(CH_2)_2O(CH_2)_2-$; and Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula II are those where Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

Other particularly preferred compounds of Formula II are those where X, Y and Z are all CH.

Other preferred compounds of the invention have Formula III



III

wherein Ar, R_1 , R_2 , and R_3 are as defined above for Formula I;


and

X and Z are independently N or $C-R_7$, wherein R_7 is hydrogen, C_3 -

C_7 cycloalkyl, or C_1 - C_6 alkyl.

More preferred compounds of Formula III are those where R_3 is C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl(C_1 - C_3)alkyl. Other more preferred compounds of Formula III are those where R_1 and R_2 independently represent C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl(C_1 - C_6)alkyl, $-(CH_2)_2O(CH_2)_2-$; and Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula III are those where Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

Still other preferred compounds of the invention have formula:



IV

wherein

wherein Ar, R_1 , R_2 , and R_3 are as defined above for Formula I;

and


W, X, and Z are independently N or $C-R_7$, wherein R_7 is hydrogen, C_3 - C_7 cycloalkyl, or C_1 - C_6 alkyl.

Preferred compounds of Formula IV are those where X and Z are both CH.

More preferred compounds of Formula IV are those where R₃ is C₁-C₄ alkyl or C₃-C₆ cycloalkyl(C₁-C₃)alkyl. Other more preferred compounds of Formula IV are those where R₁ and R₂ independently represent C₁-C₆ alkyl, C₃-C₇ cycloalkyl(C₁-C₆)alkyl, -(CH₂)₂O(CH₂)₂-; and Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula IV are those where Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

Other particularly preferred compounds of IV are those where W is CH and X and Z are both CH.

Yet other preferred compounds of the invention have formula:




V

wherein Ar, R₁, R₂, and R₃ are as defined above for Formula I;
and

X and Z are independently N or C-R₇, wherein R₇ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

Preferred compounds of Formula V are those where R₃ is C₁-C₄ alkyl or C₃-C₆ cycloalkyl(C₁-C₃)alkyl. Other more preferred compounds of Formula V are those where R₁ and R₂ independently represent C₁-C₆ alkyl, C₃-C₇ cycloalkyl(C₁-C₆)alkyl, - (CH₂)₂O(CH₂)₂-; and Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula V are those where Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

The invention also provides intermediates useful in preparing compounds of Formula I. These intermediates have Formulae VI-X.




VI

where Ar, and X, Y and Z are defined as above for Formula I.

Preferred compounds of Formula VI are those where Y is CH or N and X and Z are CH, and Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point

of attachment of Ar to the methylene group. Particularly preferred compounds of the Formula VII are those where Y is CH or N, X and Z are CH, and Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the methylene group.




VII

where R_8 is NH_2 or $N=C(R_3)C(R_7)$ where R_3 and R_7 are as defined above for Formula I; and

Ar , and X , Y and Z are defined as above for Formula I.


Preferred compounds of Formula VII are those where Y is CH or N and X and Z are CH, and Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the bicyclic ring system. Particularly preferred compounds of the Formula VII are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the bicyclic ring system.



VIII

where R_9 is halogen or hydroxy; and R_3 , R_7 , Ar, and X, Y and Z are defined as above for Formula I.


5 Preferred compounds of Formula VIII are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula VIII are those where Y is CH
 10 or N; X and Z are CH; and Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.



IX

where R_{10} is NH_2 or $NHC(O)R_3$, where R_3 is as defined above for Formula I; and Ar, and X, Y and Z are defined as above for Formula I.

Preferred compounds of Formula IX are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the bicyclic ring system. Particularly preferred compounds of the Formula IX are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the bicyclic ring system.



X

where R₃, Ar, X, Y and Z are defined as above for Formula I.

Preferred compounds of Formula X are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system. Particularly preferred compounds of the Formula X are those where Y is CH or N; X and Z are CH; and Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

In certain situations, the compounds of Formula I may contain one or more asymmetric carbon atoms, so that the

compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis
5 or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column.

Representative compounds of the present invention, which
10 are encompassed by Formula I, include, but are not limited to the compounds in Table I and their pharmaceutically acceptable acid addition salts. In addition, if the compound of the invention is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt.
15 Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts
20 from base compounds.

Non-toxic pharmaceutical salts include salts of acids such as hydrochloric, phosphoric, hydrobromic, sulfuric, sulfinic, formic, toluenesulfonic, methanesulfonic, nitric, benzoic, citric, tartaric, maleic, hydroiodic, alkanolic such as acetic,
25 $\text{HOOC}-(\text{CH}_2)_n\text{-COOH}$ where n is 0-4, and the like. Those skilled

in the art will recognize a wide variety of non-toxic pharmaceutically acceptable addition salts.

The present invention also encompasses the acylated prodrugs of the compounds of Formula I. Those skilled in the art will recognize various synthetic methodologies which may be employed to prepare non-toxic pharmaceutically acceptable addition salts and acylated prodrugs of the compounds encompassed by Formula I.

Where a compound exists in various tautomeric forms, the invention is not limited to any one of the specific tautomers. The invention includes all tautomeric forms of a compound.


By "C₁-C₆ alkyl" or "lower alkyl" in the present invention is meant straight or branched chain alkyl groups having 1-6 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. Preferred C₁-C₆ alkyl groups are methyl, ethyl, propyl, butyl, cyclopropyl and cyclopropylmethyl.

By "C₁-C₆ alkoxy" or "lower alkoxy" in the present invention is meant straight or branched chain alkoxy groups having 1-6 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyl, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.

By the term "halogen" in the present invention is meant fluorine, bromine, chlorine, and iodine.

Representative pyrido[2,3-b]indolizine derivatives and their aza analogues of the present invention are shown in Table 1. The number below each compound is its compound number.

Table 1



The interaction of compounds of the invention with CRF receptors is shown in the examples. This interaction results

in the pharmacological activities of these compounds as illustrated in relevant animal models.

The compounds of general formula I may be administered orally, topically, parenterally, by inhalation or spray or
5 rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition,
10 there is provided a pharmaceutical formulation comprising a compound of general formula I and a pharmaceutically acceptable carrier. One or more compounds of general formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or
15 adjuvants and if desired other active ingredients. The pharmaceutical compositions containing compounds of general formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft
20 capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of
25 sweetening agents, flavoring agents, coloring agents and

preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose,

hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene
5 oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene
10 sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more
15 coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such
20 as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the
25 addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. 5 Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions of the invention may also be 10 in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring 15 phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. The emulsions may 20 also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The 25 pharmaceutical compositions may be in the form of a sterile

injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable
5 preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
10 In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

15 The compounds of general formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the
20 rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

Compounds of general formula I may be administered parenterally in a sterile medium. The drug, depending on the
25 vehicle and concentration used, can either be suspended or


dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.


The preparation of the pyrido[2,3-b]indolizines and aza analogues thereof of the present invention is illustrated in Schemes I and II. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention.

Scheme I



In Scheme I, the variables Ar, R₁, R₂, R₃, R₇, X, Y, and Z are defined as above for Formula I.

Scheme II



In Scheme I, the variables Ar, R_1 , R_2 , R_3 , X, Y, and Z are
 5 defined as above for Formula I.


The disclosures of all articles and references mentioned
 in in this application, including patents, are incorporated
 herein by reference.

The preparation of the compounds of the present invention
 10 is illustrated further by the following examples which are not
 to be construed as limiting the invention in scope or spirit to
 the specific procedures and compounds described in them.

Commercial reagents were used without further
 purification. DMSO refers to dimethyl sulfoxide. THF refers
 15 to tetrahydrofuran. DMF refers to dimethylformamide. Room
 temperature refers to 20 to 25°C. Concentration in vacuo
 implies the use of a rotary evaporator. Chromatography refers
 to flash column chromatography performed using 32-63 mm silica


gel. Proton NMR chemical shifts are reported in parts per million (d) relative to tetramethylsilane as an internal standard.

5

Example 1A. 2-(2-Pyridinyl)-2-(2,4,6-trimethylphenyl)ethanenitrile

A mixed solution of 2-(2,4,6-trimethylphenyl)ethanenitrile (20g; 0.126 mol) and 2-bromopyridine (35g; 0.22 mol) in DMSO (25mL) is added to a solution of potassium t-butoxide (35g; 0.31 mol) dissolved in DMSO (125mL) dropwise slowly over a 1-hour period. After the addition, the mixture is further stirred for 4 hours at room temperature and then slowly poured into a stirred, ice-cold solution of ammonium chloride with vigorous stirring. The resulting tan precipitate is filtered, pressed, washed with methanol, and air-dried to give 20g of the title compound as a pale yellow solid (67%) : ¹H nmr (400MHz, CDCl₃) d 2.30 (s, 6 H), 2.32 (s, 3 H), 5.76 (s, 1 H), 6.93 (s, 2 H), 7.12 (d, 1 H), 7.21 (dd, 1 H), 7.63 (t, 1 H), 8.63 (d, 1 H).


B. Ethyl 2-amino-1-(2,4,6-trimethylphenyl)indolizine-3-carboxylate



5 Ethyl bromoacetate (23mL; 0.21 mol) is added slowly dropwise over a 3-hour period to a mixture of 2-(2-pyridinyl)-2-(2,4,6-trimethylphenyl)-ethanenitrile (22.3g; 0.094 mol) and potassium carbonate (78g; 0.57 mol) suspended in DMSO (100mL). The mixture is stirred for 1 day, poured into an aqueous
10 ammonium chloride solution (ca. 1L), and extracted with three 200mL portions of ethyl ether. Combined extracts are washed with saturated brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue is dissolved in THF (200mL), cooled to 0°C, and potassium t-butoxide (12g; 0.11
15 mol) is added slowly in portions over a 10-minute period. After 30 minutes at 0°C, the mixture is diluted with aqueous ammonium chloride and extracted twice with 150mL portions of 50% ethyl ether in hexane. The combined extracts are washed with saturated brine, dried (Na₂SO₄), filtered, concentrated
20 in vacuo, and chromatographed (5 to 10% ethyl acetate in hexane) to give 19.2g of the title compound as an oil (63%):
¹H nmr (400MHz, CDCl₃) δ 1.47 (t, 3 H), 2.06 (s, 6 H), 2.35

(s, 3 H), 4.46 (br q, 2 H), 6.6 (br t, 1 H), 6.75 (d, 1 H), 6.9 (br t, 1 H), 7.00 (s, 2 H), 9.4 (br 1 H).


5 C. 4-Hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]-indolizine



To a solution of 2-amino-3-ethoxycarbonyl-1-(2,4,6-trimethylphenyl)-indolizine (19.2g; 59.6 mmol) in 2,2-dimethoxypropane (100mL) is added dl-camphorsulfonic acid (0.2g). The mixture is stirred at reflux for 30 minutes and then distilled slowly to remove ca. 60mL of volatiles over a 30-minute period. The solution is cooled to ambient temperature under an inert atmosphere, diluted with anhydrous toluene (50mL), and concentrated in vacuo. The residue is dissolved in toluene (50mL) and to the stirred solution is then added a 0.5M solution of potassium bis(trimethylsilyl)amide in toluene (250mL; 125 mmol) dropwise over a 1-hour period. After the addition is complete, the mixture is further stirred for 2 hours at room temperature before being concentrated in vacuo to a small volume and then diluted with aqueous ammonium chloride. The resulting emulsion-like biphasic mixture is

suction-filtered and washed successively with water, methanol, and ethyl ether. Air- and vacuum drying provides 10.1g of the title compound as a pale yellow solid (54%).


5 D. 4-Chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]-indolizine



A solution of 4-hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrido-[2,3-b]indolizine (10.1g; 32 mmol) in phosphorus oxychloride (60mL) is heated at 100°C for 1 hour, cooled to room temperature, and concentrated in vacuo. The residue is partitioned into ice water and dichloromethane. The aqueous phase is separated and extracted twice with dichloromethane. The combined organics are washed with a 1 N aqueous sodium hydroxide solution and then with water. The solution is dried (Na₂SO₄), filtered, and concentrated in vacuo, and the resulting dark residue is filtered through a short pad of silica gel and washed with 25% ethyl acetate in hexane. The filtrate is concentrated in vacuo to give 10.1g of the title compound as a yellow solid (94%) : ¹H nmr (400MHz, CDCl₃) δ 2.00 (s, 6 H), 2.37 (s, 3 H), 2.64 (s, 3 H),

6.58 (t, 1 H), 6.95 (dd, 1 H), 7.00 (s, 2 H), 7.07 (s, 1 H),
7.08 (d, 1 H), 9.26 (d, 1 H).

5 E. 4-(N,N-Dipropyl)amino-2-methyl-10-(2,4,6-trimethylphenyl)-pyrido[2,3-b]indolizine



A mixture of 4-chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]indolizine (10.0g; 30 mmol) and
10 dipropylamine (15mL; 1 mol) in DMSO (30mL) is heated at 130°C under nitrogen atmosphere for two days. The mixture is cooled to room temperature, diluted with water (ca. 300mL), and extracted with ether (100mL x 2). The combined organics are washed successively with saturated ammonium chloride and
15 saturated brine, dried (Na₂SO₄), filtered, and concentrated. The concentrate is chromatographed (first with 5% ethyl acetate in hexane and then with 10% triethylamine in hexane) to give 10.4g of the title compound (compound 1, Table 1) as a fluorescent yellow foam (87 %) : ¹H nmr (400MHz, CDCl₃) δ 0.90
20 (t, 6 H), 1.6 (br, 4 H), 2.02 (s, 6 H), 2.37 (s, 3 H), 2.62

(s, 3 H), 3.2 (br, 4 H), 6.52 (t, 1 H), 6.73 (s, 1 H), 6.89 (t, 1 H), 7.00 (s, 2 H), 7.06 (d, 1 H), 8.98 (d, 1 H).

The following compounds are prepared essentially according to the procedures set forth above in Example 1.

Example 2

4-(N-Cyclopropanemethyl)propylamino-2-methyl-10-(2,4,6-trimethyl-phenyl)pyrido[2,3-b]indolizine (Compound 2; Table 1)

10

Example 3

4-(1-Morpholino)-2-methyl-10-(2,4,6-trimethyl-phenyl)pyrido[2,3-b]indolizine (Compound 3; Table 1)


Example 4

15

4-(N,N-Bis(2-methoxyethyl)amino)-2-methyl-10-(2,4,6-trimethyl-phenyl)pyrido[2,3-b]indolizine (Compound 4; Table 1)


Example 5

20 A. 4-Hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indolizine



A solution of 2-amino-3-cyano-1-(2,4,6-trimethylphenyl)indolizine (220mg) in an acetic anhydride (0.5mL) - acetic acid (2mL) mixture is heated at 100°C for 1 hour. The mixture is cooled to room temperature and concentrated in vacuo. The residue is then heated in 85% phosphoric acid (5mL) at 100°C for 1.5 hours, allowed to cool to room temperature, diluted with water, and neutralized to pH 7 by adding aqueous ammonium hydroxide. The resulting yellow suspension is extracted twice with dichloromethane and the combined extracts are dried (Na₂SO₄), filtered, concentrated, and chromatographed (50% ethyl acetate in hexane to 10% methanol in ethyl acetate) to give 120mg of the title compound as a yellow solid.


15 B. 4-Chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indolizine



A solution of 4-hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido-[4,5-b]indolizine (120mg) in phosphorus oxychloride (2mL) is heated at 100°C for 2 hours, cooled to room temperature, and concentrated in vacuo. The

residue is partitioned into ice water and dichloromethane. The aqueous phase is separated and extracted twice with dichloromethane. The combined organic extracts are washed with a saturated sodium bicarbonate solution and subsequently dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting dark residue is chromatographed on silica gel (10% to 20% ethyl acetate in hexane) to give 54 mg of the title compound as a greenish yellow foam : ¹H nmr (400MHz, CDCl₃) δ 1.99 (s, 6 H), 2.38 (s, 3 H), 2.79 (s, 3 H), 6.80 (m, 1 H), 7.00 (s, 2 H), 7.19 (m, 2 H), 9.27 (d, 1 H).

C. 4-(N-Benzylethylamino)-2-methyl-10-(2,4,6-trimethylphenyl)-pyrimido[4,5-b]indolizine



15

A mixture of 4-Chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido-[4,5-b]indolizine (15mg) and N-benzylethylamine (0.04mL) in DMSO (0.4mL) is heated to 110°C for 2 hours. The mixture is allowed to cool, diluted with aqueous ammonium chloride, and extracted twice with 50% ethyl ether in hexane. The combined extracts are washed with

saturated brine, dried (Na_2SO_4), filtered, and concentrated in vacuo. Chromatography (10% to 20% ethyl acetate in hexane) gives 22mg of the title compound (compound 5, Table 1) as a yellow oil : ^1H nmr (400MHz, CDCl_3) d 1.17 (t, 3 H), 2.00 (s, 6 H), 2.38 (s, 3 H), 2.70 (s, 3 H), 3.40 (q, 2 H), 4.72 (s, 2 H), 6.68 (t, 1 H), 7.00 (s, 2 H), 7.03 (d, 1 H), 7.13 (d, 1 H), 7.29 (d, 1 H), 7.35 (t, 2 H), 7.41 (d, 2 H), 8.61 (d, 1 H).

10 The following compounds are prepared essentially according to the procedures set forth above in Example 5.

Example 6

4-(N-Cyclopropanemethyl)propylamino-2-methyl-10-(2,4,6-trimethyl-phenyl)pyrimido[4,5-b]indolizine. (Compound 7)


15

Example 7

4-(N,N-Bis-(2-methoxyethyl)amino)-2-methyl-10-(2,4,6-trimethyl-phenyl)pyrimido[4,5-b]indolizine. (Compound 8)


Example 8

20 A. 2-Pyrazinyl-2-(2,4,6-trimethylphenyl)ethanenitrile



A mixture of 2-(2,4,6-trimethylphenyl)ethanenitrile (1.6g) and chloro-pyrazine (1.6g) in THF (6mL) is slowly added dropwise to an ice-cold solution of potassium t-butoxide (3.4g) in THF (10mL). After the addition, the mixture is further stirred at 0°C for 30 minutes and then diluted with aqueous ammonium chloride. The resulting mixture is extracted twice with ethyl ether and the combined extracts are washed with saturated brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography (20 to 33% ethyl acetate in hexane) gives 2.15g of the title compound as a beige solid : ¹H nmr (400MHz, CDCl₃) δ 2.30 (s, 9 H), 5.78 (s, 1 H), 6.95 (s, 2 H), 8.46 (s, 1 H), 8.54 (d, 1 H), 8.60 (d, 1 H).


15 B. Ethyl 2-amino-1-(2,4,6-trimethylphenyl)pyrrolo[1,2-
alpyrazine-2-carboxylate



To a mixture of 2-pyrazinyl-2-(2,4,6-trimethylphenyl)ethanenitrile (1.6g) and potassium carbonate (2.8g) suspended in DMF (10mL) at 0°C is added a solution of ethyl bromoacetate (1.0mL) in DMF (2mL) slowly dropwise over a


15-minute period. After the addition, the mixture is further stirred at 0°C for 1 hour, diluted with aqueous ammonium chloride, acidified with HCl to a pH of about 7. The resulting precipitate is filtered and air-dried to give 2.5g
5 of a dark, greenish solid. The solid is redissolved in THF (10mL) and treated with potassium t-butoxide (1.0 M solution in THF, 7.5mL) at 0°C. After 30 minutes, the mixture is diluted with aqueous ammonium chloride and extracted twice with ethyl ether. The combined extracts are washed with
10 saturated brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography (20 to 33% ethyl acetate in hexane) gives 0.40g of the title compound as a yellow oil : ¹H nmr (400MHz, CDCl₃) d 1.48 (t, 3 H), 2.02 (s, 6 H), 2.38 (s, 3 H), 4.50 (q, 2 H), 4.6 (br, 2 H, NH₂), 7.01 (s, 2 H), 7.69 (d, 1
15 H), 8.25 (s, 1 H), 9.0 (br, 1 H).

C. 4-Hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrido-[2',3':4,5]pyrrolo[1,2-a]pyrazine



A catalytic amount of dl-camphorsulfonic acid is added to a solution of ethyl 2-amino-1-(2,4,6-trimethylphenyl)pyrrolo[1,2-a]pyrazine-2-carboxyl-ate (0.40g) in 2,2-dimethoxypropane (10mL) and the mixture is heated to reflux for 30 minutes. Over this period, about 5 mL of volatiles are removed by slow distillation; the remaining material is further refluxed for another 15 minutes. The mixture is cooled to room temperature and concentrated in vacuo. The residue is dissolved in THF (6mL), cooled to 0°C. to the cooled solution is added dropwise a 1.0 M solution of sodium bis(trimethylsilyl)amide in THF (2.5mL). After the addition, the deep red solution is allowed to warm to room temperature and stirred for 2 additional hours before being diluted with aqueous ammonium chloride and extracted with three portions of dichloromethane. The combined organic extracts are dried (Na₂SO₄), filtered, concentrated in vacuo, and triturated with hot ethyl acetate. The product, which precipitates upon cooling and dilution with ethyl ether, is filtered and air-dried (220mg). The filtrate is concentrated in vacuo and another crystallization in minimal ethyl acetate and ether provides an additional 100mg crop of the title compound as a light yellow solid : ¹H nmr (400MHz, CDCl₃) δ 2.0 (s, 6 H), 2.38 (s, 3 H), 2.40 (s, 3 H), 6.14 (s, 1 H), 7.04 (s, 2 H), 7.81 (d, 1 H), 8.2 (br, 1 H), 8.60 (s, 1 H), 8.43 (d, 1 H).

D. 4-Chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2',3':4,5]-pyrrolo[1,2-a]pyrazine




5

A solution of 4-Hydroxy-2-methyl-10-(2,4,6-trimethylphenyl)pyrido-[2',3':4,5]pyrrolo[1,2-a]pyrazine (220mg) in phosphorus oxychloride (2mL) is heated to 100°C for 1 hour. The resulting dark tan solution is concentrated in vacuo, diluted with water, and neutralized by adding saturated sodium bicarbonate solution. The neutralized solution is extracted 3 times with dichloromethane and the combined extracts are dried (Na₂SO₄), filtered, concentrated, and chromatographed on silica gel (10 to 20% ethyl acetate in hexane) to give 120mg of the title compound as a yellow foam :

¹H nmr (400MHz, CDCl₃) d 2.03 (s, 5 H), 2.38 (s, 3 H), 2.69 (s, 3 H), 7.03 (s, 2 H), 7.25 (s, 1 H), 7.66 (d, 1 H), 8.70 (s, 1 H), 9.00 (d, 1 H).

E. 4 - (N,N-Dipropyl) amino-2-methyl-10- (2,4,6-trimethylphenyl) -
pyrido[2',3':4,5]pyrrolo[1,2-a]pyrazine



5 To a solution of 4-Chloro-2-methyl-10-(2,4,6-trimethylphenyl)pyrido-[2',3':4,5]pyrrolo[1,2-a]pyrazine (23mg) in DMSO (0.5mL) is added dipropylamine (0.1mL) and the resulting mixture is heated at 130°C for 3.5 days. The mixture is then allowed to cool to room temperature, diluted
10 with aqueous ammonium chloride, and extracted twice with ethyl ether. The extracts are combined, washed with saturated brine, dried (Na₂SO₄), filtered, concentrated in vacuo, and chromatographed (10 to 20% ethyl acetate in hexane) to give
15 14.3mg of the title compound (compound 6, Table 1) as a yellow, glassy oil : 0.90 (t, 6 H), 1.6 (m, 4 H), 2.03 (s, 6 H), 2.38 (s, 3 H), 2.62 (s, 3 H), 3.2 (br, 4 H), 6.81 (s, 1 H), 7.02 (s, 2 H), 7.60 (d, 2 H), 8.6 (m, 2 H).

The following compounds are prepared essentially according
20 to the procedures set forth above in Example 8.

Example 9

4 - (1-Morpholino) - 2-methyl-10 - (2,4,6-trimethylphenyl)pyrido - [2',3':4,5]pyrrolo[1,2-a]pyrazine.
(Compound 9)

5

Example 10

4 - (N,N-Bis - (2-methoxyethyl) amino) - 2-methyl-10 - (2,4,6-trimethyl-phenyl)pyrido - [2',3':4,5]pyrrolo[1,2-a]pyrazine.
(Compound 10)

10

Example 11

The pharmaceutical utility of compounds of the invention is indicated by the following assay.

Assay for CRF receptor binding activity


15 CRF receptor binding is performed using a modified version of the assay described by Grigoriadis and De Souza (Biochemical, Pharmacological, and Autoradiographic Methods to Study Corticotropin-Releasing Factor Receptors. *Methods in Neurosciences*, Vol. 5, 1991). Membrane pellets containing CRF
20 receptors are resuspended in 50mM Tris buffer pH 7.7 containing 10 mM MgCl₂ and 2 mM EDTA and centrifuged for 10 minutes at 48000g. Membranes are washed again and brought to a final concentration of 1500mg/ml in binding buffer (Tris buffer above with 0.1 % BSA, 15 mM bacitracin and .01 mg/ml
25 aprotinin.). For the binding assay, 100 ml of the membrane

preparation is added to 96 well microtube plates containing 100
ml of ¹²⁵I-CRF (SA 2200 Ci/mmol, final concentration of 100 pM)
and 50 ml of drug. Binding is carried out at room temperature
for 2 hours. Plates are then harvested on a Brandel 96 well
5 cell harvester and filters are counted for gamma emissions on a
Wallac 1205 Betaplate liquid scintillation counter. Non-
specific binding is defined by 1 mM cold CRF. IC₅₀ values are
calculated with the non-linear curve fitting program RS/1 (BBN
Software Products Corp., Cambridge, MA). The binding affinity
10 for the compounds of the invention, expressed as an IC₅₀ value,
generally ranges from about 0.5 nanomolar to about 10
micromolar.

The invention and the manner and process of making and
15 using it, are now described in such full, clear, concise and
exact terms as to enable any person skilled in the art to which
it pertains, to make and use the same. It is to be understood
that the foregoing describes preferred embodiments of the
present invention and that modifications may be made therein
20 without departing from the spirit or scope of the present
invention as set forth in the claims. To particularly point
out and distinctly claim the subject matter regarded as
invention, the following claims conclude this specification.

WHAT IS CLAIMED IS:

1. A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

5 Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at
10 least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;

R₁ and R₂ independently represent

C₁-C₆ alkyl;
15 C₃-C₇ cycloalkyl;
C₃-C₇ cycloalkyl(C₁-C₆)alkyl;
C₁-C₆ alkoxy(C₁-C₆)alkyl; or
aryl(C₁-C₆)alkyl where aryl is phenyl, 1- or 2-naphthyl,
2-, 3-, or 4-pyridyl, 2- or 3-thienyl or 2-, 4 or 5-
20 pyrimidyl, each of which is optionally mono- or disubstituted with halogen, hydroxy, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, or (C₁-C₆ alkylene)-A-R₄,

wherein A is O, S, NH, or N(C₁-C₆ alkyl) and R₄ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl; or

R₁ and R₂ taken together represent -(CH₂)_n-A-(CH₂)_m- wherein n is 2, 3 or 4, A is methylene, oxygen, sulfur, or NR₅,
5 wherein R₅ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl, and m is 0, 1, or 2;

R₃ is C₁-C₆ alkyl; or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S, NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl; and

10 W, X, Y, and Z are independently nitrogen or C-R₇, wherein R₇ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

2. A compound according to claim 1, where W, X, Y and Z are CH.

15

3. A compound according to claim 1, wherein W is nitrogen and X, Y, and Z are CH.

4. A compound according to claim 1, wherein W is CH.

20

5. A compound according to claim 4, wherein R₃ is C₁-C₄ alkyl or C₃-C₆ cycloalkyl(C₁-C₃)alkyl.

6. A compound according to claim 5, wherein R_1 and R_2 independently represent C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl(C_1 - C_6)alkyl, or $-(CH_2)_2O(CH_2)_2-$.

5 7. A compound according to claim 6, wherein Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

10 8. A compound according to claim 7, wherein Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

15 9. A compound according to claim 3, wherein R_3 is C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl(C_1 - C_3)alkyl.

10. A compound according to claim 9, wherein R_1 and R_2 independently represent C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl(C_1 -
20 C_6)alkyl, or $-(CH_2)_2O(CH_2)_2-$.

11. A compound according to claim 10, wherein Ar is phenyl trisubstituted with C_1 - C_3 alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the
25 tricyclic ring system.

12. A compound according to claim 11, wherein Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

13. A compound according to claim 1, wherein Y is nitrogen and X and Z are CH.

14. A compound according to claim 13, wherein W is nitrogen.

15. A compound according to claim 14, wherein R₃ is C₁-C₄ alkyl or C₃-C₆ cycloalkyl(C₁-C₃)alkyl.

16. A compound according to claim 15, wherein R₁ and R₂ independently represent C₁-C₆ alkyl, C₃-C₇ cycloalkyl(C₁-C₆)alkyl, or -(CH₂)₂O(CH₂)₂-.

17. A compound according to claim 16, wherein Ar is phenyl trisubstituted with C₁-C₃ alkyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

18. A compound according to claim 17, wherein Ar is phenyl trisubstituted with methyl in the 2, 4, and 6 positions relative to the point of attachment of Ar to the tricyclic ring system.

5

19. A compound according to Claim 1 which is 4-(N,N-dipropyl)amino-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]indolizine.

10

20. A compound according to Claim 1 which is 4-(N-cyclopropanemethyl)-propylamino-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]indolizine.

15

21. A compound according to Claim 1 which is 4-(1-morpholino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]indolizine.

20

22. A compound according to Claim 1 which is 4-(N,N-bis(2-methoxy-ethyl)amino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2,3-b]indolizine.

25


23. A compound according to Claim 1 which is 4-(N-benzylethylamino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indolizine

25. A compound according to Claim 1 which is 4-(N,N-bis-(2-methoxy-ethyl)amino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indolizine.

27. A compound according to Claim 1 which is 4-(1-morpholino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2',3':4,5]pyrrolo[1,2-a]pyrazine.

28. A compound according to Claim 1 which is 4-(N,N-bis-(2-methoxyethyl)amino)-2-methyl-10-(2,4,6-trimethylphenyl)pyrido[2',3':4,5]-pyrrolo[1,2-a]pyrazine.

29. A compound of the formula:




wherein

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;

X, Y, and Z are independently nitrogen or C-R₇, wherein R₇ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

30. A compound of the formula:



wherein


R₈ is NH₂ or N=C(R₃)C(R₇) where R₃ is C₁-C₆ alkyl; or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S, NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl; and

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at

least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted;

X, Y, and Z are independently nitrogen or C-R₇, wherein each R₇ is independently hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

31. A compound of the formula:



wherein


R₉ is halogen or hydroxy;

R₃ is C₁-C₆ alkyl; or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S, NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl;

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted; and

X, Y, and Z are independently nitrogen or C-R₇, wherein each R₇ is independently hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

5 32. A compound of the formula:




where R₁₀ is NH₂ or NHC(O)R₃;

R₃ is C₁-C₆ alkyl; or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S, NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl;

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 4- or 5-pyrimidyl, each of which is optionally mono-, di-, or trisubstituted with halogen, trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at least one of the positions ortho or para to the point of attachment of Ar to the tricyclic ring system is substituted; and

X, Y, and Z are independently nitrogen or C-R₇, wherein each R₇ is independently hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆ alkyl.

33. A compound of the formula:



wherein

R₃ is C₁-C₆ alkyl; or (C₁-C₆ alkylene)-G-R₆, wherein G is O, S,

5 NH, or N(C₁-C₆ alkyl) and R₆ is hydrogen, C₃-C₇ cycloalkyl,
or C₁-C₆ alkyl;

Ar is phenyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-
thienyl, 4- or 5-pyrimidyl, each of which is optionally
mono-, di-, or trisubstituted with halogen,
10 trifluoromethyl, hydroxy, amino, carboxamido, C₁-C₆ alkyl,
C₃-C₇ cycloalkyl, or C₁-C₆ alkoxy, with the proviso that at
least one of the positions ortho or para to the point of
attachment of Ar to the tricyclic ring system is
substituted; and

15 X, Y, and Z are independently nitrogen or C-R₇, wherein each R₇
is independently hydrogen, C₃-C₇ cycloalkyl, or C₁-C₆
alkyl.

INTERNATIONAL SEARCH REPORT

International Application No

PC./US 99/12990

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/14 C07D471/04 C07D487/04 C07D213/57 C07D241/12
//A61K31/44, A61K31/505, A61K31/495, (C07D471/14, 221:00, 221:00,
209:00), (C07D471/14, 239:00, 221:00, 209:00), (C07D471/14, 241:00,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 08847 A (PFIZER) 5 March 1998 (1998-03-05) claim 1 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 October 1999

Date of mailing of the international search report

27/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12990

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 221:00, 209:00), (C07D471/04, 221:00, 209:00), (C07D487/04, 241:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 128, no. 25, 1998 Columbus, Ohio, US; abstract no. 308500a, SHIRAISHI ET AL.: "Preparation of '(alpha-heterocyclylbenzylidene)amino!guan idine derivatives as sodium-proton exchange inhibitors" page 591; XP002118593 abstract and Chemical Substance Index 13860, column 2 (57-63)'206357-72-4! and 14210, column 2(73-79)'206357-35-9! & JP 10 114744 A (TAKEDA) 6 May 1998 (1998-05-06) --- -/--	29



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 October 1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12990

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A. BUSCHAUER: "Zur Synthese primärer omega-Phenyl-omega-pyridylalkylamine" ARCHIV DER PHARMAZIE., vol. 322, no. 3, 1989, pages 165-171, XP002118586 VERLAG CHEMIE. WEINHEIM., DE compounds 3b-f, 3j-3l, 3n, 3p, 3q ---	29
X	R.J. WOLTERS ET AL.: "Conformationally constrained analogs of mescaline II" JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 64, no. 12, 1975, pages 2013-14, XP002118587 AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON., US ISSN: 0022-3549 compound V ---	29
X	F. SAUER ET AL.: "Synthesis of substituted phenyl pyridinyl and phenyl pyrimidinyl ketones" JOURNAL OF CHEMICAL RESEARCH. SYNOPSES, no. 7, 1977, page 186 XP002118588 LONDON, GB ISSN: 0308-2342 compounds 3 (X=2-C1, 4-C1, 2, 6-C12) ---	29
X	M. CARDELLINI ETAL.: "Interaction of some 2-hydroxybenzylpiperidines with dopamine receptors" FARMACO., vol. 42, no. 4, 1987, pages 307-317, XP002118589 SOCIETA CHIMICA ITALIANA, PAVIA., IT ISSN: 0014-827X compound VIIb ---	29
X	A.R. KATRIZZKY ET AL.: "2-Pyrazinyl-2-arylalkanenitriles" JOURNAL OF CHEMICAL AND ENGINEERING DATA, vol. 32, no. 4, 1987, pages 479-81, XP002118590 Washington, US compounds 2b-2d --- -/--	29

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12990

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A. RAKEEB EL AL.: "An investigation of the influence of haloarenes and hetarylacetonitriles on the competition between possible aryne arylation and tandem addition-rearrangement pathways" HETEROCYCLES., vol. 34, no. 6, 1992, pages 1239-49, XP002118591 XX, XX ISSN: 0385-5414 compounds 4ba,4ca,4ea,4fa ----	29
X	US 3 932 431 A (WALTER) 13 January 1976 (1976-01-13) example 7 (27-34) ----	29
P,X	F. HEROLD EL AL.: "Synthesis and structure of novel 4-arylhexahydro-1H,3H-pyrido[1,2-c]pyrimidine derivatives" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 36, no. 2, 1999, pages 389-96, XP002118592 HETEROCORPORATION. PROVO., US ISSN: 0022-152X compounds 1b,1e,1h -----	29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/12990

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9808847 A	05-03-1998	AU 3456197 A EP 0923582 A HR 970454 A NO 990927 A	19-03-1998 23-06-1999 31-08-1998 26-02-1999
JP 10114744 A	06-05-1998	NONE	
US 3932431 A	13-01-1976	US 3770737 A	06-11-1973